Continued effect of intermittent subcutaneous apomorphine following long-term use in patients with advanced Parkinson's disease

被引：0
|
作者：
Pfeiffer, DF
机构：
来源：
MOVEMENT DISORDERS | 2004年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P814
引用
收藏
页码：S281 / S282
页数：2
相关论文
共 50 条
  • [21] Long-term clinical and cognitive follow up in patients with advanced Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation
    Isaias, I. U.
    Rodolfi, G.
    Landi, A.
    Natuzzi, F.
    Pezzoli, G.
    Antonini, A.
    JOURNAL OF NEUROLOGY, 2009, 256 : S16 - S17
  • [22] Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson's disease patients☆
    Camgrand, Eva
    Christine, Brefel-Courbon
    Harroch, Estelle
    Chouquet, Cecile
    Barthelemy, Christel
    Ory-Magne, Fabienne
    Leung, Clemence
    Barbosa, Raquel Pinhero
    Rascol, Olivier
    Fabbri, Margherita
    PARKINSONISM & RELATED DISORDERS, 2023, 116
  • [23] A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease
    Hilary L. Tyne
    Jan Parsons
    Ann Sinnott
    Susan H. Fox
    Nicholas A. Fletcher
    Malcolm J. Steiger
    Journal of Neurology, 2004, 251 : 1370 - 1374
  • [24] A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease
    Tyne, HL
    Parsons, J
    Sinnott, A
    Fox, SH
    Fletcher, NA
    Steiger, MJ
    JOURNAL OF NEUROLOGY, 2004, 251 (11) : 1370 - 1374
  • [25] Long-term subcutaneous administration of apomorphine or insulin for Parkinson's disease or diabetes and skin event rates
    Wells, K.
    Zhou, S.
    Engelhard, J.
    Oleske, D.
    Werner, B.
    Facheris, M.
    Zamudio, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 515 - 515
  • [26] Subcutaneous Apomorphine Infusion Therapy in Advanced Parkinson's Disease: Long-Term Follow-Up of Effectivity, Tolerability and Patient Satisfaction
    Sixel-Doering, F.
    Klinke, H.
    Hahn, K.
    Ebersbach, G.
    Odin, P.
    Trenkwalder, C.
    AKTUELLE NEUROLOGIE, 2011, 38 : S27 - S33
  • [27] Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up
    Pietz, K
    Hagell, P
    Odin, P
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 65 (05): : 709 - 716
  • [28] COST COMPARISON OF DEEP DRAIN STIMULATION (DBS) AND CONTINUED SUBCUTANEOUS APOMORPHINE INFUSION (CSAI) IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
    Autiero, Walleser S.
    Eggington, S.
    Valyi, A.
    VALUE IN HEALTH, 2014, 17 (07) : A395 - A395
  • [29] A 10-year retrospective audit of long-term apomorphine use in Parkinson's disease
    Tyne, HL
    Parsons, J
    Sinnott, A
    Fox, S
    Steiger, MJ
    Fletcher, NA
    MOVEMENT DISORDERS, 2002, 17 : S75 - S76
  • [30] Long-term efficacy of istradefylline in patients with advanced Parkinson's disease
    Mark, MH
    MOVEMENT DISORDERS, 2005, 20 : S93 - S93
12345